Opendata, web and dolomites

DIVE into AD SIGNED

Study of tau strains to understand the phenotypic diversity of Alzheimer’s disease: A step toward personalized therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DIVE into AD project word cloud

Explore the words cloud of the DIVE into AD project. It provides you a very rough idea of what is the project "DIVE into AD" about.

phenotypes    hallmark    cerebrospinal    biomarkers    suffering    confirmed    neurodegeneration    metabolism    aggregates    correlates    dementia    neuron    modifies    behaves    treatment    native    therapies    detect    single    plan    progression    spread    responsible    prion    therapeutic    heterogeneity    human    majority    ad    2050    cell    technologies    millions    pathological    fluid    deep    variants    conformation    modern    alzheimer    beta    rate    pathophysiology    signatures    respective    vast    repertoire    patient    optimize    samples    care    deposition    strains    event    unsuccessfully    ageing    individual    fidelity    template    biosensor    clinical    patterns    understand    expression    propagate    gender    lines    accumulation    generate    morphology    discrete    peptide    diversity    societies    neuronal    determinants    conformers    brain    innovative    differences    cognition    vulnerability    patients    seem    disease    sensitively    postulate    ultimately    course    causative    citizens    tau    protein    pathology    19    potentially    shown    treat    variability   

Project "DIVE into AD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE GENEVE 

Organization address
address: RUE DU GENERAL DUFOUR 24
city: GENEVE
postcode: 1211
website: www.unige.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 278˙840 €
 EC max contribution 278˙840 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-GF
 Starting year 2020
 Duration (year-month-day) from 2020-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE GENEVE CH (GENEVE) coordinator 278˙840.00
2    THE GENERAL HOSPITAL CORPORATION US (BOSTON MA) partner 0.00

Map

 Project objective

Dementia represents a major challenge for our ageing societies. The number of citizens suffering from dementia in the EU is expected to reach 19 millions by 2050. Alzheimer’s disease (AD) is responsible for the vast majority of dementia cases. However there is still not a single available treatment that modifies the course of disease. Therefore, the development of innovative approaches to better understand the pathophysiology and ultimately treat patients must be a priority. This project aims to understand the determinants of the diversity of AD clinical phenotypes through the deep analysis of pathological variants of the tau protein. As the accumulation of Aβ peptide has long been considered a causative event in AD, most therapeutic approaches have targeted Aβ metabolism, but unsuccessfully. Modern biomarkers, have confirmed that the brain deposition of tau pathology, the other hallmark of AD, correlates much better with human cognition and neurodegeneration. Recently, it was shown that tau behaves like a prion and can spread from one neuron to another. Moreover, tau strains or conformers seem to template native tau and propagate the pathological conformation with high fidelity. Discrete tau strains generate distinct aggregates morphology or patterns of neuronal vulnerability. I postulate that different strains of tau are responsible for the variability of AD and may determine the progression rate, gender differences or clinical expression. Therefore, my objective is to develop the technologies to identify tau strains signatures in distinct AD phenotypes. In particular, I plan to develop and optimize biosensor cell lines that sensitively detect tau strains from human brain samples and cerebrospinal fluid, and characterize respective repertoire of tau strains. Understanding AD heterogeneity would potentially increase our ability to take care of every individual patient. In addition, this work could lead to the development of biomarkers and novel targeted therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIVE INTO AD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIVE INTO AD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

MetEpiC (2020)

P53-dependent Metabolic and Epigenetic Reprogramming in Carcinogenesis

Read More